ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase 2a clinical candidate TXL, a novel, highly potent analog of the successful antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to Viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus. ContraVir’s third candidate and lead clinical drug, Valnivudine, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, Valnivudine has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.
|Size (employees)||14 (est)|
Net income (Q3, 2018)
EBIT (Q3, 2018)
Market capitalization (12-Dec-2018)
Closing stock price (12-Dec-2018)
|USD||Q1, 2014||Q2, 2014||Q1, 2016||Q2, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q1, 2018||Q2, 2018||Q3, 2018|
General and administrative expense
Operating expense total
Depreciation and amortization
|USD||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q1, 2018||Q2, 2018||Q3, 2018|
Depreciation and Amortization
Cash From Operating Activities
ContraVir Pharmaceuticals has 569 Twitter Followers. The number of followers has decreased 0.1% month over month and increased 2.1% quarter over quarter
When was ContraVir Pharmaceuticals founded?
ContraVir Pharmaceuticals was founded in 2013.
Who are ContraVir Pharmaceuticals key executives?
ContraVir Pharmaceuticals's key executives are Robert Foster, John Cavan and Gary S. Jacob.
How many employees does ContraVir Pharmaceuticals have?
ContraVir Pharmaceuticals has 14 employees.
Who are ContraVir Pharmaceuticals competitors?
Competitors of ContraVir Pharmaceuticals include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.
Where is ContraVir Pharmaceuticals headquarters?
ContraVir Pharmaceuticals headquarters is located at 399 Thornall St, Edison.
Where are ContraVir Pharmaceuticals offices?
ContraVir Pharmaceuticals has offices in Edison, Edmonton and Doylestown.
How many offices does ContraVir Pharmaceuticals have?
ContraVir Pharmaceuticals has 3 offices.